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Introduction
The success of combination highly active antiretroviral 
therapy (HAART) for advanced human immunodeficiency 
virus (HIV) infection, introduced in 1996,1 marked the 
beginning of an era that would result in HAART becoming the 
principal regimen used to treat millions of HIV-infected adults 
and children worldwide. Unfortunately, the agents used in 
these multi-drug regimens are not without side-effects, and 
nucleoside reverse transcriptase inhibitors (NRTIs), included 
in most regimens, are responsible for significant morbidity 
and mortality mostly associated with lipoatrophy and severe 
lactic acidosis in patients on HAART.2-7 NRTIs were known 
by the early 1990s to be mitochondrial toxins causing 
mitochondrial deoxyribonucleic acid (mtDNA) depletion.8 
Since then, toxic effects have been well characterised, 
less toxic NRTIs have been developed and the risk factors 
associated with mitochondrial toxicity have been identified.9 
However, what has remained elusive is the ability to identify 
preclinical mitochondrial toxicity and in so doing prevent 
NRTI-associated morbidity. 
More recently, HIV infection itself has emerged as a 
cause of mitochondrial dysfunction, further complicating 
the diagnosis and management of NRTI-associated 
mitochondrial toxicity. These factors, combined with recent 
data suggesting that NRTIs in addition may undermine 
mitochondrial DNA integrity, have renewed concern over 
the long-term side-effects of these agents, particularly in 
growing children who could very well be exposed to them 
for life. 
Objectives
The objectives of this review can be summarised as follows:
• To describe the basic physiology of mitochondrial 
function and how this relates to the pathophysiology 
of NRTIs and HIV infection regarding mitochondrial 
function.
• To describe the history of research in the field of HIV-
associated mitochondrial toxicity, citing important 
studies that have contributed significantly towards our 
current understanding of the problem and discussing 
the major strengths and weaknesses of these studies.
• To identify areas requiring further research.
Background
Mitochondria are found in all human cells, with the 
exception of mature red blood cells, and host a number 
of essential biochemical reactions largely concerned 
with fuel oxidation and adenosine triphosphate 
production.10 In addition, mitochondria are intimately 
involved in a number of cellular processes, including cell 
differentiation, signalling and division, and are recognised 
as being critically involved in programmed cell death, or 
apoptosis, and ageing.10-12 Mitochondria also contain 
their own unique circular DNA, an evolutionary remnant 
that, at 16.5 kilobases, contains 37 genes that code 
for 13 respiratory chain peptides, together with two 
ribosomal ribonucleic acids (rRNAs) and 22 transfer 
ribonucleic acids (tRNAs) involved in mitochondrial 
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protein synthesis.13,14 Most mitochondria contain at least 
two copies of mtDNA, and the number of mitochondria 
in cells range from a couple of hundred to hundreds of 
thousands in tissues with high energy demands, such as 
muscle, renal tubular cells and neurons.14,15 
Mitochondria and their DNA are maternally inherited, 
derived directly from thousands of maternal oocytic 
mitochondria. A number of maternally inherited 
mitochondrial cytopathies with specific mutations in the 
mitochondrial DNA are well described.14 Two principles 
govern the manifestation of inherited mitochondrial 
disease. Firstly, the “threshold effect” describes the fact 
that dysfunctional mitochondria need to reach a critical 
threshold before a tissue manifests with mitochondrial 
failure, as a result of the high reserve of oxidative capacity 
inherent in most tissues. Secondly, mitochondria 
are randomly distributed in the growing zygote in a 
process known as “heteroplasmy”. This means that two 
patients with identical mtDNA mutations may manifest 
with different tissue symptoms due to differences 
in the diseased mitochondrial load in each tissue.14 
Mitochondrial DNA is replicated by the enzyme DNA 
polymerase γ, an enzyme that performs both polymerase 
and exonuclease activities and differs from the nuclear 
DNA (nDNA) polymerases in that it is more susceptible 
to interference by a number of nucleotide analogues 
designed to inhibit HIV reverse transcriptase.16
Nucleoside reverse transcriptase 
inhibitors and mitochondrial DNA 
integrity
Phosphorylated nucleoside analogues interfere with 
viral reverse transcriptases by actively competing 
with endogenous nucleotides for incorporation into 
the growing nucleic acid chain. After incorporation, 
they prevent chain elongation as they do not contain a 
3’-hydroxyl group for addition to the next nucleotide.17-19 
Examples are shown in Figure 1.
In this manner, NRTIs have been shown to interfere 
with mtDNA polymerase γ in vitro,17 causing depletion 
of mtDNA that is assumed to result in mitochondrial 
dysfunction. Lipoatrophy is a common manifestation 
of mitochondrial dysfunction, and less frequent 
complications include potentially fatal lactic acidosis, 
skeletal myopathy, cardiomyopathy, neuropathy, 
pancreatitis and nephro-toxicity that usually manifests 
as tubulopathy2,20-27 Although all NRTIs potentially affect 
mtDNA polymerase γ, didanosine (ddI) and stavudine 
(d4T) have repeatedly been implicated in the most 
severe cases of mitochondrial toxicity with fatal lactic 
acidosis.28-30 
Apart from their direct effect on mtDNA polymerase 
γ, nucleoside analogues may also compete with 
endogenous nucleosides for phosphorylation by 
mitochondrial thymidine kinase 2 and also for transport 
into the mitochondria.31,32 Evidence is now emerging 
that NRTIs may increase the rate of accumulation of 
mtDNA mutations, and increased mutations have been 
demonstrated longitudinally in peripheral leukocytes in 
Figure 1: Selected endogenous nucleosides and their corresponding antiviral drug analogues
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patients on HAART.33 In addition, Maagaard et al found 
increased mtDNA deletions in the skeletal muscle of 
patients exposed to NRTIs,34 and reduced mitochondrial 
gene expression has been demonstrated in adipocytes 
exposed to NRTIs.35-37 Taken together, this evidence 
suggests that NRTIs as a group may have far-reaching 
effects on mitochondrial function in the short as well 
as long term. Regarding predisposing risk factors for 
NRTI mitochondrial toxicity, obese adult women 
are known to be at increased risk.9,38 Furthermore, 
genetic predisposition linked to the mitochondrial 
DNA sequence also appears to play a role. Individuals 
belonging to mitochondrial haplogroup T, which is best 
characterised as a European mitochondrial lineage, have 
a higher incidence of NRTI-associated neuropathy,39 
and more recently a known T9098C polymorphism in 
the mitochondrial gene for adenosine 5’-triphosphate 
synthase subunit 6 has been associated with severe 
mitochondrial toxicity in a child after in utero exposure to 
zidovudine (AZT) and lamivudine (3TC).40 
HIV and mitochondrial function
HIV causes apoptosis and cellular death in many tissues, 
most notably in immune cells such as CD4 lymphocytes. 
It is not surprising therefore that given the importance of 
mitochondria in regulating cellular apoptosis, HIV should 
exploit mitochondrial apoptotic pathways to initiate 
destruction of immune cells involved in the immune 
response against infection. Apoptosis is triggered by two 
major pathways: the first through exogenous factors that 
bind cell membrane receptors such as Fas ligand (FasL; 
CD178) and ultimately give rise to cytoplasmic caspase 
8 and 10 activation through a cytoplasmic signaling 
pathway, leading to apoptosis; and the second through 
intrinsic factors within the cell that trigger cytochrome 
C and other proapoptotic factors to be released from 
the mitochondrial intermembrane space, which in turn 
result in caspase 9 activation and apoptosis.41,42 HIV is 
implicated in both of these pathways. 
A number of HIV proteins have been shown to activate 
apoptosis directly and initiate cell death, the most 
important of these being Env, Nef, Tat and viral protein R 
(Vpr). Env, also known as gp-120, together with Nef and 
Tat, has been shown to activate the extrinsic apoptotic 
pathway through the Fas/FasL receptor,43-45 and Env, Nef, 
Tat and Vpr have all been shown to trigger cytochrome 
C release from the mitochondrial intermembrane space 
with subsequent caspase activation through the internal 
pathway. This form of HIV-induced apoptosis has been 
demonstrated in CD4 cells, haematopoietic cells, cardiac 
myocytes and neurons.46-49 In addition to the direct 
effect of HIV-1 viral proteins, the massive inflammatory 
response and immune activation associated with HIV 
and the associated cytokines, including tissue necrosis 
factor α, interleukin 2 and interferon α, are also capable 
of inducing apoptosis.50-52 
It is clear from the above mechanisms that both NRTIs 
and HIV infection itself directly influence mitochondrial 
function in a number of tissues, HIV infection by 
activating mitochondrial apoptotic pathways to trigger 
cell death and NRTIs by directly or indirectly interfering 
with mtDNA integrity. It is therefore not surprising that 
the clinical manifestations of HIV organ pathology and 
NRTI mitochondrial toxicity should overlap in a number of 
organs with high dependence on mitochondrial function. 
Examples include neuropathy, renal tubulopathy, 
lipodystrophy and myopathy that may be associated 
with either agent.  
Research history of nucleoside reverse 
transcriptase inhibitor toxicity
The mechanism of nucleoside analogue interference 
with mtDNA polymerase γ and the subsequent depletion 
of mitochondrial DNA were first described in 1990 in 
early cases of AZT-associated myopathy.8,53,54 In 1995 
Lewis and Dalakas put forward their “polymerase 
gamma hypothesis” based on the principle that tissues 
dependent on high levels of oxidative phosphorylation, 
where NRTIs were incorporated and phosphorylated, 
were most likely to manifest with mitochondrial 
dysfunction.55 With the widespread use of dual NRTIs in 
HAART regimens and the associated increase in cases 
of fatal lactic acidosis, researchers looked for markers 
that could predict mitochondrial toxicity. Blood lactate 
was the obvious choice and lactate has been extensively 
measured and monitored in large cohorts of patients 
on antiretroviral treatment (ART) combination regimens. 
Many of these studies confirmed the increased relative 
risk of lactataemia with d4T- and ddI- vs. AZT-based 
regimens.56 However, lactate measurement as a predictive 
marker of decompensated mitochondrial toxicity was 
limited by the fact that many patients on full-time NRTI 
therapy and neonatal recipients of short courses of 
NRTIs have asymptomatic hyperlactataemia that does 
not progress to decompensated lactataemia.57,58 Also, 
lactate lacks specificity and is influenced by technical 
and physiological variability.59
Another approach was to quantify mtDNA against 
nDNA using real-time polymerase chain reaction (PCR) 
techniques in peripheral blood leukocytes (PBLs), mainly 
to avoid invasive tissue biopsies. Most techniques 
employ separation of a leukocyte buffy coat from 
platelets because platelets contain mitochondria but 
not nDNA, which could theoretically confound results. 
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Quantitation is usually performed by simultaneous real-
time PCR amplification with fluorometric detection of a 
mitochondrial and a nuclear gene, and the results are 
either expressed as mtDNA:nDNA ratios or as absolute 
mtDNA copies per cell if separate commercial mtDNA 
and nDNA standards are used.60,61 This approach yielded 
promising data in 2002 when Coté et al followed up 
eight HIV-infected hyperlactataemic patients on NRTIs 
longitudinally. The authors found significant depletion 
of PBL mtDNA in these patients, that improved after 
cessation of therapy to levels comparable to 47 ART-
naïve HIV-infected patients.28 In addition, the authors 
reported lower levels of PBL mtDNA in the ART-naïve 
HIV-infected patients vs. 24 uninfected controls. The 
strength of this study was the fact that it was the first 
to demonstrate the clinical application of PBL mtDNA 
quantitation as a marker of NRTI mitochondrial toxicity 
and could be used as a laboratory marker for this 
purpose, but its weakness lay in the fact that the patients 
selected for longitudinal study all had overt symptomatic 
hyperlactataemia on NRTI regimens of d4T or d4T/ddI, 
drugs already known to be associated with a high risk 
for lactataemia.29,62,63 The study was therefore unable 
to demonstrate whether PBL mtDNA could be used to 
detect presymptomatic mitochondrial toxicity before the 
onset of clinical lactataemia or improve on the specificity 
or sensitivity of lactate as a marker of mitochondrial 
toxicity. 
Subsequent to this work, a number of studies were 
conducted to evaluate PBL mtDNA in HIV-infected 
cohorts to answer these questions.35,61,64-69 Five adult 
studies confirmed the findings of Coté et al, namely that 
PBL mtDNA levels in ART-naïve HIV-infected patients 
were depleted vs. HIV-negative control groups but not 
significantly different from ART-exposed patients, and a 
single cross-sectional study in South Africa demonstrated 
the same findings in a paediatric population.70 However, 
conflicting findings occurred in the small (n=10) study by 
Henry et al64 that demonstrated no difference between 
HAART- exposed patients and healthy controls, and in 
the longitudinal study of Miura et al67 that demonstrated 
complete amelioration of PBL mtDNA depletion to 
normal levels with AZT/3TC-based HAART, suggesting 
that HIV was the major cause of depleted PBL mtDNA. 
These findings have more recently been supported by 
Aldrovandi et al who measured PBL mtDNA in babies 
exposed to NRTIs in utero and as neonates. The authors 
found that PBL mtDNA was decreased in HIV-exposed 
neonates compared to controls, but was higher in ART/
HIV-exposed neonates than HIV-exposed neonates 
who were not exposed to ART.71 These data support 
the notion that HIV itself, and not NRTIs, is the major 
contributor towards PBL mtDNA depletion. Regarding 
ART-exposed patients in larger studies, Chiappini et al,65 
Coté et al68 and De Mendoza et al66 all found lower levels 
of PBL mtDNA associated with d4T, DDI and particularly 
d4T/DDI combination regimens. In the largest of these, a 
cross-sectional study by Coté et al,68 of 214 ART-treated 
individuals exposed to ART for more than four months, 
clearly demonstrated progressive PBL mtDNA depletion 
with d4T/ddI, ddI, d4T and AZT combinations, in this 
order. Today, neither d4T nor ddI are recommended 
for first-line HAART regimens and have been replaced 
by safer NRTI combination regimens, owing to their 
association with mitochondrial toxicity. Stavudine is 
currently only used as a first-line drug in resource-
constrained settings because of its lower cost. 
As a result of the conflicting findings with PBL mtDNA 
measurement, researchers turned their attention 
to tissue mtDNA quantitation. Mitochondrial DNA 
measured in renal biopsies of patients without HIV, 
with HIV on tenofovir (TDF) treatment  and with HIV 
without TDF, demonstrated reduced mtDNA levels in 
both HIV-infected groups vs. uninfected biopsies, but 
no difference between the two HIV-infected groups, 
suggesting that HIV itself also contributed toward 
mtDNA depletion in renal tissue.72 Adipose tissue mtDNA 
measured in a large cohort of HIV-infected individuals 
with lipodystrophy on HAART demonstrated depleted 
mtDNA levels vs. controls and a significant association 
between d4T, ddI and mtDNA depletion.73 However, 
this work was limited by the fact that only two HIV-
infected ART-naïve patients were studied, and so the 
contribution of HIV infection to adipose tissue mtDNA 
depletion was not assessed.73 More recently, Garrabou 
et al found significant mtDNA depletion and reduced 
mitochondrial oxidative function in adipocytes of HIV-
infected ART-naïve individuals compared to uninfected 
controls.74 The value of tissue mtDNA measurement has 
been questioned by Kim et al,75 who confirmed findings 
of depleted mtDNA in adipose tissue of lipoatrophic 
HAART-treated patients, but found no decrease in 
mtDNA-dependent mitochondrial function and an actual 
compensatory increase in nuclear-driven mitochondrial 
biogenesis, suggesting that mtDNA depletion was not 
a good marker for mitochondrial function. In another 
cross-sectional study by Magaard et al,34 mitochondrial 
DNA was lower in muscle biopsies from 24 patients 
with HIV on HAART than 10 ART-naïve HIV patients, 
but both groups demonstrated decreased PBL mtDNA 
compared to 11 healthy controls. The authors concluded 
that PBL mtDNA does not correlate with organ mtDNA 
depletion. Taken together, the measurement of mtDNA 
in end organs appears to deliver similar information to 
PBL measurements, namely that NRTIs, particularly d4T 
and ddI, cause tissue mtDNA depletion. HIV infection 
response and immune activation associated with HIV 
and the associated cytokines, including tissue necrosis 
factor α, interleukin 2 and interferon α, are also capable 
of inducing apoptosis.50-52 
It is clear from the above mechanisms that both NRTIs 
and HIV infection itself directly influence mitochondrial 
function in a number of tissues, HIV infection by 
activating mitochondrial apoptotic pathways to trigger 
cell death and NRTIs by directly or indirectly interfering 
with mtDNA integrity. It is therefore not surprising that 
the clinical manifestations of HIV organ pathology and 
NRTI mitochondrial toxicity should overlap in a number of 
organs with high dependence on mitochondrial function. 
Examples include neuropathy, renal tubulopathy, 
lipodystrophy and myopathy that may be associated 
with either agent.  
Research history of nucleoside reverse 
transcriptase inhibitor toxicity
The mechanism of nucleoside analogue interference 
with mtDNA polymerase γ and the subsequent depletion 
of mitochondrial DNA were first described in 1990 in 
early cases of AZT-associated myopathy.8,53,54 In 1995 
Lewis and Dalakas put forward their “polymerase 
gamma hypothesis” based on the principle that tissues 
dependent on high levels of oxidative phosphorylation, 
where NRTIs were incorporated and phosphorylated, 
were most likely to manifest with mitochondrial 
dysfunction.55 With the widespread use of dual NRTIs in 
HAART regimens and the associated increase in cases 
of fatal lactic acidosis, researchers looked for markers 
that could predict mitochondrial toxicity. Blood lactate 
was the obvious choice and lactate has been extensively 
measured and monitored in large cohorts of patients 
on antiretroviral treatment (ART) combination regimens. 
Many of these studies confirmed the increased relative 
risk of lactataemia with d4T- and ddI- vs. AZT-based 
regimens.56 However, lactate measurement as a predictive 
marker of decompensated mitochondrial toxicity was 
limited by the fact that many patients on full-time NRTI 
therapy and neonatal recipients of short courses of 
NRTIs have asymptomatic hyperlactataemia that does 
not progress to decompensated lactataemia.57,58 Also, 
lactate lacks specificity and is influenced by technical 
and physiological variability.59
Another approach was to quantify mtDNA against 
nDNA using real-time polymerase chain reaction (PCR) 
techniques in peripheral blood leukocytes (PBLs), mainly 
to avoid invasive tissue biopsies. Most techniques 
employ separation of a leukocyte buffy coat from 
platelets because platelets contain mitochondria but 
not nDNA, which could theoretically confound results. 
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may cause depletion independently, but this is likely 
to be a tissue-dependent phenomenon, and mtDNA 
levels in tissue do not correlate with PBL mtDNA levels 
or with actual mitochondrial function, as a result of the 
initiation of compensatory mechanisms to preserve 
essential mitochondrial functions. Currently most 
authors have concluded that measurement of mtDNA 
in PBLs and tissue contributes little toward predicting 
NRTI-induced functional mitochondrial toxicity, and 
mtDNA measurements are not used in routine practice, 
though there may still be some value in performing serial 
measurements of PBL mtDNA in at-risk individuals.
Other methods used for direct assessment of 
mitochondrial function without invasive tissue biopsy 
include measurement of lymphocyte mitochondrial 
transmembrane potential by flow cytometry and 13C 
methionine breath testing.76-78 Flow cytometric techniques 
employ a cationic lipophilic fluorochrome with an 
affinity for mitochondria with high membrane potential. 
This method has the added advantage that circulating 
leukocyte subsets are easily separated and compared. 
Using flow cytometry, Polo et al found mitochondrial 
dysfunction independently associated with HIV infection 
and the use of d4T, in concordance with the findings of 
others.79 The 13C methionine breath test assesses hepatic 
mitochondrial function by quantification of exhaled13 
CO2 after oral methionine loading and is based on the 
fact that intact mitochondrial metabolism is required for 
methionine catabolism. Using this method, Milazzo et al 
found reduced 13CO2 excretion in HIV-infected patients 
on AZT- or d4T-based regimens when compared to ART-
naïve controls, with further reductions in lactataemic 
patients. No differences were apparent between healthy 
controls and infected ART-naïve patients. The authors 
concluded that hepatic mitochondrial dysfunction is 
drug related as opposed to HIV related and that the 13C 
methionine breath test is superior to lactate measurement 
for detection of subclinical toxicity.77
Paediatric HIV presents additional scenarios where 
children who do not contract HIV are exposed to ART, 
either in utero during maternal treatment, or perinatally 
during prevention of mother to child transmission 
(PMTCT) of HIV. In addition, most HIV-infected children 
are not ART naïve prior to initiation of therapy, and 
clinical mitochondrial dysfunction has been described 
in over 30% of perinatally infected children followed up 
longitudinally.80 Mitochondrial toxicity associated with 
PMTCT was highlighted in 1999 when eight HIV-uninfected 
children in a French cohort exposed to AZT and/or 3TC 
presented with severe mitochondrial dysfunction, and 
two died.81 Subsequent prospective cohort studies have 
been conflicting, with some reporting evidence for an 
increased incidence of mitochondrial dysfunction up to 
18 months post-PMTCT,82 and others not.83,84 Despite 
this, transient hyperlactataemia that rarely progresses 
to fatal lactic acidosis in ART-exposed neonates is well 
known.57,58 Based on the outcomes of the South African 
arm of the Children with HIV Early Antiretroviral Therapy 
(CHER) study,85 treatment guidelines for paediatric HIV 
have been changed and now include ART for all HIV-
infected children under 12 months of age, regardless 
of clinical condition.86 In addition, a move to reduce the 
use of d4T in resource-constrained settings is being 
advocated, with substitution of d4T with TDF in adults 
and abacavir in children as one of the first-line NRTIs.86   
Further research
No study to date has managed to answer a number of 
pressing questions regarding the combination effect 
of HIV infection and NRTIs on mitochondrial function. 
A number of these questions may only be answered in 
longitudinal studies and all are particularly applicable to 
children. Research questions that need to be answered 
are the following:
What are the long-term complications of NRTIs, specifically 
regarding mitochondrial DNA integrity and its effect on 
growth, ageing and end-organ function, and to what extent 
are tissues able to compensate for NRTI-induced mtDNA 
depletion?
Are the mitochondrial effects of HIV infection and NRTIs 
synergistic? In other words, are patients with severe HIV 
disease at higher risk of mitochondrial toxicity from NRTIs 
than patients with less severe HIV disease, and if so, which 
tissues are most likely to be affected? This question is 
especially relevant in resource-constrained settings where 
access to ART is limited and many patients have more 
severe disease prior to initiation of treatment with regimens 
often containing d4T.
While safer, cost-effective ART is developed, is there 
another laboratory marker or tissue-specific marker that 
can be used to identify patients at high risk of NRTI toxicity 
pre-emptively so that preventative management can be 
employed in time? 
Conclusion
The availability of HAART has made an enormous 
contribution worldwide to the treatment of people living with 
HIV infection, and the focus has now shifted to prevention of 
the long-term side-effects of the drugs used in the treatment 
of this disease. While lipodystrophy and its associated 
metabolic changes are associated with protease inhibitors, 
the major toxic effect of NRTIs is fatal decompensated 
lactic acidosis due to mitochondrial toxicity. There is also 
growing concern about the cumulative long-term effects of 
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a class of drugs that influence mtDNA synthesis and repair. 
Although the availability of safer ART regimens has reduced 
the incidence of severe toxicity, new drugs are often not 
available in resource-constrained settings where the majority 
of patients with HIV are found, and though measures to limit 
NRTI toxicity, such as regimen switching, are available, 
there is a pressing need to implement protocols that 
promote the use of safer first-line NRTIs and restrict the use 
of d4T. It is also crucial to continue further research into 
the understanding and prevention of ART-related toxicity, 
particularly as it relates to children with HIV. 
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